

# Acrochordons as a Cutaneous Sign of Metabolic Syndrome: A Case-Control Study

Shah R, Jindal A<sup>1</sup>, Patel NM<sup>1</sup>

Department of Medicine, Civil Hospital, <sup>1</sup>Department of Dermatology, Smt. S.C.L. Hospital, Ahmedabad, Gujarat, India

**Address for correspondence:**

Dr. Anchal Jindal,  
A-133, Ext. 2, Shalimar Garden,  
Sahibabad, Ghaziabad - 201 005,  
Uttar Pradesh, India.  
E-mail: drjindal28@gmail.com

## Abstract

**Background:** Acrochordons (known as skin tags) are benign skin tumors. A few studies with contradictory results have been reported regarding the abnormalities of carbohydrate and/or lipid metabolisms in patients with skin tags. **Aim:** The aim of this study is to determine if the presence of acrochordons could be a marker of Metabolic syndrome by comparing with a control group. **Subjects and Methods:** A total of 110 patients having two or more acrochordons and age- and gender-matched 110 controls were included in the study. Localization, size and the total number of acrochordons were recorded in the patient group. Age, sex, body mass index (BMI), waist circumference, smoking status, fasting plasma glucose (FPG), impaired glucose tolerance (IGT) test, insulin resistance, serum lipids and liver enzyme levels were estimated in cases and controls. Arterial blood pressures were measured in two groups. **Results:** A total of 58 patients and 12 controls were diagnosed with overt diabetes mellitus (DM). 15% (16/110) of patients and 8% (9/110) of controls had an IGT test. The difference was statistically significant for the diagnosis of DM and not significant for the IGT. The mean levels of FPG, BMI, insulin resistance, total cholesterol, low-density lipoprotein cholesterol and triglyceride were significantly higher in patients than those in controls. Serum levels of high-density lipoprotein were less in patients. Patients with acrochordons had higher systolic and diastolic blood pressures than controls. **Conclusion:** Acrochordons may represent a cutaneous sign for Metabolic syndrome. Changing the life-style of these patients may have a beneficial role.

**Keywords:** Acrochordons, Metabolic, Syndrome

## Introduction

Acrochordons, also known as skin tags or soft fibromas, are common, small, soft, usually pedunculated and benign skin tumors that are most often found on the neck, axilla or groin. They are protrusions of the loose fibrous tissue. They usually vary in diameter from 2 mm to 6 mm in diameter and are skin colored although larger and hyperpigmented lesions can be seen in dermatological examination. Although acrochordons are benign, common and of little significance they have been observed in increased frequency with systemic disorders such as acromegaly and colonic polyps.<sup>[1,2]</sup>

Touraine proposed a possible association of acrochordons with diabetes mellitus (DM) in 1951.<sup>[3]</sup> Since then, a few clinical studies with conflicting results have been reported to clarify this hypothesis.<sup>[4-7]</sup> In the present study, we aimed to evaluate a possible relationship of acrochordons with DM, hyperlipidemia, hypertension and liver enzyme abnormalities.

## Subjects and Methods

The present study represents a case-control study. One hundred and ten patients having two or more acrochordons and age- and gender-matched 110 controls were enrolled in the study. Study participants were recruited consecutively from patients attending the dermatology out-patient clinic of Smt. S.C.L. Hospital from April 2012 to November 2012. Patient group was defined as population seeking advice for two or more than that number of acrochordons. Control group was age- and gender-matched apparently healthy participants with no acrochordons, randomly selected from the out-patient clinic. Exclusion criteria were pregnant females, patients taking any drugs that could alter blood glucose level, patient

Access this article online

Quick Response Code:



Website: [www.amhsr.org](http://www.amhsr.org)

DOI:  
10.4103/2141-9248.129040

having concomitant disorder(s) that could affect the outcome of the study.

The details of the study were explained to the subjects and their signed informed consent was taken prior to participation in the study. All patients and controls were asked for a complete history and underwent detailed physical examination.

In all participants, a detailed clinical history was taken followed by the dermatological examination. Localization, size, pigmentation and the total number of acrochordons were recorded in the patient group. Biopsy sample was taken from lesion and sent for histopathological examination for clinical and histopathological diagnosis confirmation. Body mass index (BMI) was calculated for the participants in both groups. Overweight was defined by BMI 25 or greater and obesity was defined by BMI 30 or greater. Laboratory investigation included the serum fasting plasma glucose (FPG) level, oral glucose tolerance test, lipid profile and liver enzyme levels.

A standard 2-h oral glucose tolerance test and arterial blood pressure measurements were also performed. DM and impaired glucose tolerance (IGT) were evaluated according to the American Diabetes Association (ADA) criteria<sup>[8]</sup> [Table 1].

Confounding factor such as systemic diseases like colonic polyps was excluded.<sup>[17]</sup> All blood pressure measurements were taken with standard calibrated mercury manometers in the right arm of each individual in a sitting position after a rest of 5 min. Defining criteria for Metabolic syndrome by International Diabetes Foundation (IDF) were used as following:<sup>[18]</sup>

For South Asians (Chinese, Malay, Asian-Indian population), waist circumference  $\geq 90$  cm for males and  $\geq 80$  cm in females is considered as central obesity.

Data were statistically described in terms of mean (standard deviation), frequency (number of cases) and percentages when appropriate. Comparison of quantitative variables between the study groups was carried out using the Student's *t*-test and Chi-squared test, respectively. Statistical calculation was carried out using the software Version 6 of Epi Info™ (Epi6) by the Centers for Disease Control and the World Health Organization ([www.cdc.gov/epo/epi/epiinfo.htm](http://www.cdc.gov/epo/epi/epiinfo.htm)).  $P < 0.05$  was considered to be statistically significant.

## Results

The age, gender distribution and other demographic data of both groups are summarized in Table 1. The mean age of the patient and control groups were 54 (36-58.3) and 51 (38-61) years, respectively [Table 2]. The most frequent localization of acrochordons was neck (42%, 46/110) followed by the axilla (25%, 27/110), the trunk (12%, 13/110), genital region (9%, 10/110) and upper extremities (3.63%, 4/110) in patient group [Table 3]. There were no gender differences

in the frequency and mean number of acrochordons in the anatomical localizations.

Nearly, 58 (52%) patients and 12 (10%) controls were diagnosed with overt DM according to ADA criteria<sup>[9]</sup> and this difference was statistically significant.

**Table 1: According to new IDF definition, for a person to be defined as having metabolic syndrome they must have: Central obesity (defined as waist circumference with ethnicity specific values) plus any two of the following four factors**

Raised triglyceride	$\geq 150$ mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality
Reduced high-density lipoprotein (HDL) cholesterol	$<40$ mg/dL (1.1 mmol/L) in males $<50$ mg/dL (1.3 mmol/L) in females or specific treatment for this lipid abnormality
Raised blood pressure	Systolic blood pressure $\geq 130$ and diastolic blood pressure $\geq 85$ mm Hg or treatment of previously diagnosed hypertension
Raised FPG	$\geq 100$ mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes mellitus

FPG: Fasting plasma glucose, IDF: International diabetes foundation

**Table 2: Demographic data of patient and control group**

Variables	Patients (n=110) mean (SD)	Controls (n=110) mean (SD)	P value*
Age (year)	54 (11)	51 (13)	0.06
Gender (female/male)	65/45	66/44	NA
BMI (kg/m <sup>2</sup> )	27.8 (7.1)	25.9 (5.2)	0.02
Total cholesterol (mg/dL)	223.9 (7.8)	180.6 (6.2)	$<0.001$
LDL cholesterol (mg/dL)	113.3 (10.2)	106.7 (8.5)	$<0.001$
HDL cholesterol (mg/dL)	30.2 (6.4)	44.0 (4.5)	$<0.001$
Triglyceride (mg/dL)	167.0 (6.5)	136 (5.2)	$<0.001$
AST (U/L)	26 (8)	20 (5)	$<0.001$
ALT (U/L)	23 (7)	16 (6)	$<0.001$
Hypertension (%)	19	6	NA
Overt diabetes mellitus (%)	58 (52)	12 (10)	NA
Impaired glucose tolerance (%)	15	8	NA
Familial DM history (%)	52	17	NA
Personal skin cancer history (%)	1.4	0	NA
Familial skin cancer history (%)	1.4	0	NA

BMI: Body mass index, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, DM: Diabetes mellitus, SD: Standard deviation. \* $P < 0.05$  is considered to be statistically significant. NA: Not applicable in these variables

**Table 3: The frequency and mean number of acrochordons in each anatomical location**

Localization	Frequency	
	Number	Percentage
Neck	78	42
Axilla	51	25
Trunk	19	12
Genital	16	9
Upper extremity	12	4
Other	17	8

\*More than one localization were recorded in many patients had acrochordons on multiple sites

However, no significant difference was noted between patients and controls regarding the IGT test (15% and 8%, respectively). Familial history for DM was significantly higher in patient group compared with the control group. Mean values of systolic and diastolic blood pressures were noted significantly higher in patients than those in controls [Table 2] and hypertension was found higher in 19% (21/110) and 6% (7/110), respectively. The univariate analysis revealed that patients showed statistically significantly higher waist circumference, FPG, triglyceride, systolic blood pressure and diastolic blood pressure compared to controls with  $P < 0.001$  [Table 4]. Correlation and regression analyses showed no significant effect of BMI, the total number, pigmentation, size and localization of acrochordons on any parameters investigated in the patient group.

## Discussion

Acrochordons have been suggested to be associated with DM and obesity since Touraine reported a possible association between them and endocrine diseases in 1951.<sup>[3]</sup> Nanney *et al.* found that growing acrochordons correlated with increased epidermal growth factor receptors (EGF-R) in the epidermis.<sup>[9]</sup> Mathur and Bhargava proposed that overexpression of EGF-R may be caused by an increase in unesterified fatty acids due to hyperinsulinemic state.<sup>[10]</sup> Morgolis reported that 32 of 40 patients (72.3%) with acrochordons had overt DM while IGT was observed in 6 (12.7%) patients.<sup>[11]</sup> Kahana *et al.* observed IGT in 34.3% of 216 patients with acrochordons and found no correlation between the localization, size, color and number of the lesions with the presence of glucose intolerance.<sup>[6]</sup> In another study, Agarwal and Nigam detected abnormality of glucose tolerance in 48 (40.6%) of 118 patients with acrochordons. Obesity was present in 21.2% of patients.<sup>[4]</sup> Norris *et al.* suggested that acrochordons correlated more closely with hyperinsulinemic state than diabetes.<sup>[12]</sup> In a study by Demir and Demir, it was found that 88 (73.3%) of 120 patients with acrochordons were found to be overt DM. They reported that the most frequent localization of the lesions was neck as in this study.<sup>[5]</sup> Contrary to this study, the authors found a positive correlation between

the number of acrochordons and BMI. Sudy *et al.* found that eight or more skin tags were related with statistically significant laboratory glucose/insulin abnormalities: Basal hyperinsulinemia, postprandial hyperinsulinemia and postprandial hyperglycemia.<sup>[13]</sup> In a recent study, Yilmaz *et al.* reported that among the pregnant women with both acrochordons and acanthosis nigricans (AN), 40% of them had gestational DM, whereas the same ratio was 12.3% for women free of both acrochordons and AN.<sup>[14]</sup>

Although these studies are important in indicating the potential association between acrochordons and systemic diseases, they did not include an evaluation of lipid profile or liver enzymes of patients with acrochordons. However, they did not have any control group for comparison.

Rasi *et al.* studied 104 patients and 94 age-, gender- and BMI-matched controls and found a positive correlation between the total number of acrochordons and FPG.<sup>[7]</sup> A total of 24 patients in acrochordon group were detected to have overt DM in their study. To the best of our knowledge, our study has the largest age- and gender-matched patient and control groups. The results of the current study are partly in line with the previous studies.

We detected overt DM in 58 (52%) of the 110 patients and 12 (10%) of the 110 controls according to ADA criteria, but contrary to the previous reports, we did not find any significant differences between two groups regarding the IGT (15% and 8%, respectively). However, familial history for DM was significantly higher in patient group compared with the control group.

There have been a few reports in the literature investigating lipid profile and hypertension in patients with acrochordons.<sup>[19-22]</sup> Crook reported an atherogenic lipid profile, increased serum triglyceride concentration and decreased HDL cholesterol in a small study group including four patients with acrochordons.<sup>[15]</sup> In a recent study, Sari *et al.* investigated 113 patients with acrochordons and 37 controls and found that the frequency of hypertension was 30.1%, dyslipidemia 59.3%, insulin resistance 21.2% and Metabolic syndrome 39.8% in the patient group. The authors also reported that the number of skin tags and distribution of the acrochordons were not related to any parameters.<sup>[16]</sup> We found higher total cholesterol, triglyceride, low-density lipoprotein cholesterol levels and lower HDL cholesterol in patients with acrochordons. Significantly higher mean systolic and diastolic arterial pressure values were also detected in patient group. To our knowledge, a possible relationship between acrochordons and liver enzyme levels has not been investigated in the previous studied. We found significantly higher serum aspartate aminotransferase and alanine aminotransferase values in patients than those in the controls and this may be a preliminary result that would make us plan new studies to investigate a possible relationship between acrochordons and liver diseases.

**Table 4: Comparison between patient and control as regard to metabolic syndrome criteria**

Variables	Mean (SD)		t*	P
	Patients (n=110)	Control (n=110)		
Waist circumference (cm)	100.5 (12.1)	82.5 (12.7)	10.8	<0.001
Systolic blood pressure (mm Hg)	132 (10)	118 (10)	10.4	<0.001
Diastolic blood pressure (mm Hg)	86 (10)	80 (5)	5.7	<0.001
Fasting blood glucose (mg/dL)	119.96 (6.2)	80.71 (5.6)	39.3	<0.001
Fasting triglyceride (mg/dL)	167 (6.5)	136 (5.2)	31	<0.001
Fasting HDL (mg/dL)	30.2 (6.4)	44.1 (4.5)	18.6	<0.001

\*Student's t test done.  $P < 0.05$  was considered to be statistically significant. SD: Standard deviation, HDL: High-density lipoprotein

## References

1. Nabarro JD. Acromegaly. *Clin Endocrinol (Oxf)* 1987;26:481-512.
2. Chobanian SJ, Van Ness MM, Winters C Jr, Cattau EL Jr. Skin tags as a marker for adenomatous polyps of the colon. *Ann Intern Med* 1985;103:892-3.
3. Touraine A. A new hereditary chain; cutaneous fibromas, diabetes, obesity. *Ann Dermatol Syphiligr (Paris)* 1951;78:409-16.
4. Agarwal JK, Nigam PK. Acrochordon: A cutaneous sign of carbohydrate intolerance. *Australas J Dermatol* 1987;28:132-3.
5. Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. *Acta Diabetol* 2002;39:57-9.
6. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: A cutaneous marker for diabetes mellitus. *Acta Derm Venereol* 1987;67:175-7.
7. Rasi A, Soltani-Arabshahi R, Shahbazi N. Skin tag as a cutaneous marker for impaired carbohydrate metabolism: A case-control study. *Int J Dermatol* 2007;46:1155-9.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2004;27 Suppl 1:S5-10.
9. Nanney LB, Ellis DL, Levine J, King LE. Epidermal growth factor receptors in idiopathic and virally induced skin diseases. *Am J Pathol* 1992;140:915-25.
10. Mathur SK, Bhargava P. Insulin resistance and skin tags. *Dermatology* 1997;195:184.
11. Margolis J Letter: Skin tags in diabetes mellitus. *N Engl J Med* 1976;295:172-3.
12. Norris PG, McFadden J, Gale E, Griffiths WA. Skin tags are more closely related to fasting insulin than fasting glucose levels. *Acta Derm Venereol* 1988;68:367-8.
13. Sudy E, Urbina F, Maliqueo M, Sir T. Screening of glucose/insulin metabolic alterations in men with multiple skin tags on the neck. *J Dtsch Dermatol Ges* 2008;6:852-5, 852.
14. Yilmaz E, Kelekci KH, Kelekci S. Skin tag and acanthosis nigricans: Do they have a predictive value for gestational diabetes mellitus? *Exp Clin Endocrinol Diabetes* 2011;119:419-22.
15. Crook MA. Skin tags and the atherogenic lipid profile. *J Clin Pathol* 2000;53:873-4.
16. Sari R, Akman A, Alpsoy E, Balci MK. The metabolic profile in patients with skin tags. *Clin Exp Med* 2010;10:193-7.
17. Chiritescu E, Maloney ME. Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome. *J Am Acad Dermatol* 2001;44:789-94.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - A new world-wide definition. A consensus statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
19. El Safoury OS, Abdel Hay RM, Fawzy MM, Kadry D, Amin IM, Abu Zeid OM, *et al.* Skin tags, leptin, metabolic syndrome and change of the life style. *Indian J Dermatol Venereol Leprol* 2011;77:577-80.
20. Shaheen MA, Abdel Fattah NS, Sayed YA, Saad AA. Assessment of serum leptin, insulin resistance and metabolic syndrome in patients with skin tags. *J Eur Acad Dermatol Venereol* 2012;26:1552-7.
21. Gorpelioglu C, Erdal E, Ardicoglu Y, Adam B, Sarifakioglu E. Serum leptin, atherogenic lipids and glucose levels in patients with skin tags. *Indian J Dermatol* 2009;54:20-2.
22. Gupta S, Aggarwal R, Gupta S, Arora SK. Human papillomavirus and skin tags: Is there any association? *Indian J Dermatol Venereol Leprol* 2008;74:222-5.

**How to cite this article:** Shah R, Jindal A, Patel NM. Acrochordons as a cutaneous sign of metabolic syndrome: A case-control study. *Ann Med Health Sci Res* 2014;4:202-5.

**Source of Support:** Nil. **Conflict of Interest:** None declared.